Study highlights the role of cellular senescence markers (p16, p21) and MMP-7 co-expression in fibrosing interstitial lung diseases.
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
Research on idiopathic pulmonary fibrosis reveals how immune infiltrate differences in early stages influence disease progression. Study highlights the role of B cells, T cells, and NK cells as potential biomarkers.
Expert consensus on patient-centred strategies to manage multimorbidity in COPD, aiming to improve outcomes and reduce disease burden.
The CAAT is a standardized 8-item questionnaire to assess health status in people with asthma, COPD, and other airway diseases. Now validated beyond COPD.
Commentary in the European Respiratory Journal (June 2025) reaffirming spirometry as the essential diagnostic tool for COPD.
Study analyzing risk factors and one-year outcomes of organizing pneumonia in COVID-19 hospitalized patients, evaluating the impact of corticosteroid treatment at different doses.
Discover how early-life genetic and environmental factors contribute to COPD and how emerging strategies aim to detect and intercept the disease early. Review from the European Respiratory Review, July 2025
Jean Wright presents at TEDxCharlotte how millions live with COPD unknowingly. It’s time to identify and help the “missing millions.”
Discover how ex vivo lung perfusion (EVLP) impacts the lung microbiome and its implications for improving donor lung viability and reducing transplant complications.
